Overall | Trial with non-add-on design | Trial with add-on design | Trials before 2008 | Trials after 2008 | |
---|---|---|---|---|---|
Number of trials | 140 | 113 | 27 | 64 | 76 |
Total sample size | 19,210 | 14,556 | 4654 | 7008 | 12,202 |
Sample size per arm* | 102 (11, 746) | 100 (11, 746) | 132 (21, 479) | 107 (14, 327) | 101 (11, 746) |
Age, years* | 73.5 (58.0, 81.7) | 73.3 (58.0, 81.7) | 74.1 (68.0, 79.4) | 73.2 (58.0, 78.9) | 73.6 (64.6, 81.7) |
Gender, male (%)* | 42.1 (0, 98.0) | 41.2 (0,67) | 43.3 (0, 98.0) | 42.6 (27.1, 67.0) | 41.9 (0, 98.0) |
Race, white (%)* | 93.7 (0, 100) | 93.1 (0, 100) | 94.1 (0, 100) | 92.6 (0, 100) | 94.1 (0, 100) |
APOE ε4 carrier, %* | 58.4 (0, 100) | 58.1 (0, 100) | 58.3 (46.6, 74.0) | 60.0 (53.0, 67.6) | 57.9 (0, 100) |
ADAS-cog 11, points* | 24.5 (13.1, 39.3) | 24.8 (13.1, 39.3) | 24.1 (17.6, 28.0) | 26.4 (16.2, 39.3) | 24.0 (13.1, 32.2) |
NPI score, points* | 9.3 (5.0, 21.8) | 9.6 (5.0, 21.1) | 9.0 (5.8, 21.8) | 11.0 (8.7, 16.1) | 9.1 (5.0, 21.8) |
MMSE score, points* | 19.4 (13.2, 25.4) | 19.4 (13.2 25.4) | 19.5 (15.6, 22.2) | 19.1 (13.2, 22.5) | 20.1 (15.6, 25.4) |
Publication year, no. (%) | |||||
Before 2008 | 64 (45.7) | 64 (61.2) | 0 (0) | – | – |
After 2008 | 76 (54.3) | 49 (38.8) | 27 (100) | – | – |